Bronchodilator Reversibility in the GAN Severe Asthma Cohort

Milger K, Skowasch D, Hamelmann E, Mümmler C, Idzko M, Gappa M, Jandl M, Körner-Rettberg C, Ehmann R, Schmidt O, Taube C, et al. (2023)
Journal of Investigational Allergology and Clinical Immunology 33(6): 446-456.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Milger, K.; Skowasch, D.; Hamelmann, EckardUniBi; Mümmler, C.; Idzko, M.; Gappa, M.; Jandl, M.; Körner-Rettberg, C.; Ehmann, R.; Schmidt, O.; Taube, C.; Holtdirk, A.
Alle
Abstract / Bemerkung
Background: Positive bronchodilator reversibility (BDR) is a diagnostic criterion for asthma. However, patients with asthma may exhibit a negative BDR response.Aim: To describe the frequency of positive and negative BDR response in patients with severe asthma and study associations with phenotypic characteristics.Methods: A positive BDR response was defined as an increase in FEV1 >200 mL and >12% upon testing with a short-acting ss-agonist.Results: BDR data were available for 793 of the 2013 patients included in the German Asthma Net (GAN) severe asthma registry. Of these, 250 (31.5%) had a positive BDR response and 543 (68.5%) a negative BDR response. Comorbidities significantly associated with a negative response were gastroesophageal reflux disease (GERD) (28.0% vs 40.0%, P<.01) and eosinophilic granulomatosis with polyangiitis (0.4% vs 3.0%; P<.05), while smoking history (active: 2.8% vs 2.2%; ex: 40.0% vs 41.7%) and comorbid chronic obstructive pulmonary disease (COPD) (5.2% vs 7.2%) were similar in both groups. Patients with a positive BDR response had worse asthma control (median Asthma Control Questionnaire 5 score, 3.4 vs 3.0, P<.05), more frequently reported dyspnea at rest (26.8% vs 16.4%, P<.001) and chest tightness (36.4% vs 26.2%, P<.001), and had more severe airway obstruction at baseline (FEV1% predicted, 56 vs 64, P<.001) and higher fractional exhaled nitric oxide (FeNO) levels (41 vs 33 ppb, P<0.05). There were no differences in diffusion capacity of the lung for carbon monoxide, single breath (% pred, 70% vs 71%). Multivariate linear regression analysis identified an association between positive BDR response and lower baseline FEV1% (P<.001) and chest tightness (P<.05) and a negative association between BDR and GERD (P<.05).Conclusion: In this real-life setting, most patients with severe asthma had a negative BDR response. Interestingly, this was not associated with smoking history or COPD, but with lower FeNO and presence of GERD.
Stichworte
Bronchodilator responsiveness; Severe asthma; Real-life cohort; GERD; FeNO
Erscheinungsjahr
2023
Zeitschriftentitel
Journal of Investigational Allergology and Clinical Immunology
Band
33
Ausgabe
6
Seite(n)
446-456
ISSN
1018-9068
eISSN
1698-0808
Page URI
https://pub.uni-bielefeld.de/record/2986298

Zitieren

Milger K, Skowasch D, Hamelmann E, et al. Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Journal of Investigational Allergology and Clinical Immunology. 2023;33(6):446-456.
Milger, K., Skowasch, D., Hamelmann, E., Mümmler, C., Idzko, M., Gappa, M., Jandl, M., et al. (2023). Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Journal of Investigational Allergology and Clinical Immunology, 33(6), 446-456. https://doi.org/10.18176/jiaci.0850
Milger, K., Skowasch, D., Hamelmann, Eckard, Mümmler, C., Idzko, M., Gappa, M., Jandl, M., et al. 2023. “Bronchodilator Reversibility in the GAN Severe Asthma Cohort”. Journal of Investigational Allergology and Clinical Immunology 33 (6): 446-456.
Milger, K., Skowasch, D., Hamelmann, E., Mümmler, C., Idzko, M., Gappa, M., Jandl, M., Körner-Rettberg, C., Ehmann, R., Schmidt, O., et al. (2023). Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Journal of Investigational Allergology and Clinical Immunology 33, 446-456.
Milger, K., et al., 2023. Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Journal of Investigational Allergology and Clinical Immunology, 33(6), p 446-456.
K. Milger, et al., “Bronchodilator Reversibility in the GAN Severe Asthma Cohort”, Journal of Investigational Allergology and Clinical Immunology, vol. 33, 2023, pp. 446-456.
Milger, K., Skowasch, D., Hamelmann, E., Mümmler, C., Idzko, M., Gappa, M., Jandl, M., Körner-Rettberg, C., Ehmann, R., Schmidt, O., Taube, C., Holtdirk, A., Timmermann, H., Buhl, R., Korn, S.: Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Journal of Investigational Allergology and Clinical Immunology. 33, 446-456 (2023).
Milger, K., Skowasch, D., Hamelmann, Eckard, Mümmler, C., Idzko, M., Gappa, M., Jandl, M., Körner-Rettberg, C., Ehmann, R., Schmidt, O., Taube, C., Holtdirk, A., Timmermann, H., Buhl, R., and Korn, S. “Bronchodilator Reversibility in the GAN Severe Asthma Cohort”. Journal of Investigational Allergology and Clinical Immunology 33.6 (2023): 446-456.

Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 36000830
PubMed | Europe PMC

Suchen in

Google Scholar